UCL Technology Fund has participated in a $145m round that will allow Apollo Therapeutics to advance assets into the clinic and open a US office.
Apollo Therapeutics, a UK-based biopharmaceutical joint venture involving University of Cambridge, Imperial College London and University College London (UCL), closed a $145m round today backed by the latter’s UCL Technology Fund.
Patient Square Capital led the transaction, which also attracted Rock Springs Capital and Reimagined Ventures.
Apollo Therapeutics was established in late 2015 by tech transfer offices Cambridge Enterprise and UCL Business together with Imperial Innovations, the commercialisation firm of Imperial College London that was subsequently acquired by…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
